End-of-day quote
Warsaw S.E.
03:30:00 02/05/2024 am IST
|
5-day change
|
1st Jan Change
|
0.52
PLN
|
0.00%
|
|
+4.84%
|
+52.94%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
4.657
|
10.75
|
23.56
|
78.54
|
29.56
|
11.57
|
Enterprise Value (EV)
1 |
11.38
|
11.99
|
24.69
|
79.51
|
29.89
|
11.97
|
P/E ratio
|
144
x
|
-20.6
x
|
-32.6
x
|
12,258
x
|
-232
x
|
435
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
10.7
x
|
20.5
x
|
40.5
x
|
293
x
|
56.2
x
|
46.6
x
|
EV / Revenue
|
26.1
x
|
22.9
x
|
42.4
x
|
296
x
|
56.8
x
|
48.2
x
|
EV / EBITDA
|
23.7
x
|
16.6
x
|
-54.9
x
|
62.6
x
|
35.2
x
|
16.1
x
|
EV / FCF
|
392
x
|
-1.4
x
|
9.91
x
|
92.1
x
|
12
x
|
-6.87
x
|
FCF Yield
|
0.26%
|
-71.5%
|
10.1%
|
1.09%
|
8.31%
|
-14.6%
|
Price to Book
|
0.92
x
|
1.05
x
|
2.48
x
|
10.2
x
|
3.91
x
|
1.53
x
|
Nbr of stocks (in thousands)
|
12,937
|
41,337
|
41,337
|
41,337
|
41,337
|
41,337
|
Reference price
2 |
0.3600
|
0.2600
|
0.5700
|
1.900
|
0.7150
|
0.2800
|
Announcement Date
|
30/05/18
|
31/05/19
|
28/05/20
|
31/05/21
|
29/04/22
|
31/05/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
0.4356
|
0.5244
|
0.5822
|
0.2683
|
0.5259
|
0.2484
|
EBITDA
1 |
0.4793
|
0.7215
|
-0.4499
|
1.27
|
0.8499
|
0.7454
|
EBIT
1 |
0.0426
|
-0.4649
|
-0.7005
|
0.0417
|
-0.0768
|
-0.209
|
Operating Margin
|
9.77%
|
-88.66%
|
-120.33%
|
15.55%
|
-14.6%
|
-84.14%
|
Earnings before Tax (EBT)
1 |
0.0323
|
-0.5217
|
-0.7232
|
0.006409
|
-0.1274
|
0.0266
|
Net income
1 |
0.0323
|
-0.5217
|
-0.7232
|
0.006409
|
-0.1274
|
0.0266
|
Net margin
|
7.41%
|
-99.5%
|
-124.22%
|
2.39%
|
-24.23%
|
10.72%
|
EPS
2 |
0.002493
|
-0.0126
|
-0.0175
|
0.000155
|
-0.003082
|
0.000643
|
Free Cash Flow
1 |
0.029
|
-8.567
|
2.492
|
0.8635
|
2.484
|
-1.743
|
FCF margin
|
6.66%
|
-1,633.85%
|
428.03%
|
321.82%
|
472.36%
|
-701.73%
|
FCF Conversion (EBITDA)
|
6.06%
|
-
|
-
|
67.99%
|
292.3%
|
-
|
FCF Conversion (Net income)
|
89.98%
|
-
|
-
|
13,473.37%
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/05/18
|
31/05/19
|
28/05/20
|
31/05/21
|
29/04/22
|
31/05/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
6.72
|
1.24
|
1.13
|
0.97
|
0.34
|
0.4
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
14.02
x
|
1.717
x
|
-2.51
x
|
0.7669
x
|
0.3972
x
|
0.5371
x
|
Free Cash Flow
1 |
0.03
|
-8.57
|
2.49
|
0.86
|
2.48
|
-1.74
|
ROE (net income / shareholders' equity)
|
0.64%
|
-6.83%
|
-7.35%
|
0.08%
|
-1.67%
|
0.35%
|
ROA (Net income/ Total Assets)
|
0.13%
|
-1.44%
|
-2.41%
|
0.17%
|
-0.29%
|
-0.82%
|
Assets
1 |
25.66
|
36.28
|
30.06
|
3.724
|
43.93
|
-3.249
|
Book Value Per Share
2 |
0.3900
|
0.2500
|
0.2300
|
0.1900
|
0.1800
|
0.1800
|
Cash Flow per Share
2 |
0
|
0
|
0
|
0
|
0.0100
|
0
|
Capex
|
-
|
10.4
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
1,986.52%
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/05/18
|
31/05/19
|
28/05/20
|
31/05/21
|
29/04/22
|
31/05/23
|
|
1st Jan change
|
Capi.
|
---|
| +52.94% | 5.35M | | +25.69% | 47.9B | | +46.90% | 41.42B | | -3.46% | 40.7B | | -6.20% | 28.92B | | +9.17% | 25.55B | | -20.42% | 19.27B | | +0.17% | 12.15B | | +28.07% | 12.14B | | -1.24% | 11.99B |
Other Biotechnology & Medical Research
|